Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,104 GBX | +0.65% | +10.19% | +13.45% |
Apr. 25 | Health Care Drops Amid Mixed Earnings -- Health Care Roundup | DJ |
Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The firm trades with high earnings multiples: 20.7 times its 2024 earnings per share.
- The company's enterprise value to sales, at 3.85 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.45% | 233B | B+ | ||
+24.17% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+6.04% | 201B | B- | ||
-10.51% | 193B | A+ | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ | ||
+2.07% | 123B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC